4D Molecular Therapeutics... (FDMT)
4D Molecular Therapeutics Statistics
Share Statistics
4D Molecular Therapeutics has 46.23M shares outstanding. The number of shares has increased by -7.13% in one year.
| Shares Outstanding | 46.23M |
| Shares Change (YoY) | -7.13% |
| Shares Change (QoQ) | -11.05% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 39.57M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 7.67M, so 16.6% of the outstanding shares have been sold short.
| Short Interest | 7.67M |
| Short % of Shares Out | 16.6% |
| Short % of Float | 20.12% |
| Short Ratio (days to cover) | 6.9 |
Valuation Ratios
The PE ratio is -7.86 and the forward PE ratio is -1.29. 4D Molecular Therapeutics's PEG ratio is 0.45.
| PE Ratio | -7.86 |
| Forward PE | -1.29 |
| PS Ratio | 38.26 |
| Forward PS | 2.2 |
| PB Ratio | 2.58 |
| P/FCF Ratio | -10.09 |
| PEG Ratio | 0.45 |
Enterprise Valuation
4D Molecular Therapeutics Inc. has an Enterprise Value (EV) of 558.34M.
| EV / Earnings | -5.54 |
| EV / Sales | 26.94 |
| EV / EBITDA | -5.21 |
| EV / EBIT | -4.95 |
| EV / FCF | -7.11 |
Financial Position
The company has a current ratio of 15.65, with a Debt / Equity ratio of 0.05.
| Current Ratio | 15.65 |
| Quick Ratio | 15.65 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.55 |
| Cash Flow / Debt | -5.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is -35%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -35% |
| Revenue Per Employee | 140.97K |
| Profits Per Employee | -685.97K |
| Employee Count | 147 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.68% in the last 52 weeks. The beta is 2.79, so 4D Molecular Therapeutics's price volatility has been higher than the market average.
| Beta | 2.79 |
| 52-Week Price Change | -84.68% |
| 50-Day Moving Average | 5.3 |
| 200-Day Moving Average | 12.79 |
| Relative Strength Index (RSI) | 40.69 |
| Average Volume (20 Days) | 886.85K |
Income Statement
In the last 12 months, 4D Molecular Therapeutics had revenue of 20.72M and earned -100.84M in profits. Earnings per share was -2.58.
| Revenue | 20.72M |
| Gross Profit | -76.37M |
| Operating Income | -112.87M |
| Net Income | -100.84M |
| EBITDA | -107.12M |
| EBIT | -112.87M |
| Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has 249.11M in cash and 14.67M in debt, giving a net cash position of 234.44M.
| Cash & Cash Equivalents | 249.11M |
| Total Debt | 14.67M |
| Net Cash | 234.44M |
| Retained Earnings | -415.33M |
| Total Assets | 604.03M |
| Working Capital | 481.29M |
Cash Flow
In the last 12 months, operating cash flow was -75.79M and capital expenditures -2.77M, giving a free cash flow of -78.56M.
| Operating Cash Flow | -75.79M |
| Capital Expenditures | -2.77M |
| Free Cash Flow | -78.56M |
| FCF Per Share | -2.01 |
Margins
Gross margin is -368.54%, with operating and profit margins of -544.65% and -486.59%.
| Gross Margin | -368.54% |
| Operating Margin | -544.65% |
| Pretax Margin | -486.59% |
| Profit Margin | -486.59% |
| EBITDA Margin | -516.9% |
| EBIT Margin | -544.65% |
| FCF Margin | -379.11% |
Dividends & Yields
FDMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -57.33% |
| FCF Yield | -37.77% |
Analyst Forecast
The average price target for FDMT is $39.5, which is 777.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.5 |
| Price Target Difference | 777.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 1.28 |
| Piotroski F-Score | 2 |